Lymphoma of the testis as primary location: tumour review.
Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma. This neoplasm is the most common malignant tumour of the testis in the elderly. The most common histotype in primary forms is the diffuse large B-cell lymphoma, whereas more aggressive histologies such as Burkitt's lymphoma are principal founded in cases of secondary involvement of the testis. Regarding clinical presentation, the most common sign is a unilateral painless scrotal swelling, sometimes with sharp scrotal pain or hydrocele. In patients with advanced stage, the systematic B symptoms are present in 25-41% of all cases. In 35% of patients, bilateral testicular involvement is detected. In more advanced stages with para-aortic lymph-node involvement, ascites and abdominal pain is evident. Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor. Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue. For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis. In more advanced or relapsed disease, management should follow the worldwide recommendations for nodal diffuse large B-cell lymphoma (DLBCL). Here we present a review of this tumour.
Koukourakis
Georgios
G
Saint Savvas Anticancer Institute of Athens, Athens Greece. gkoyokoyrakis@yahoo.gr
Kouloulias
Vassilios
V
D018450:Disease Progression; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*
Br J Cancer. 1995 Jan;71(1):73-7
7819053
Oncology. 2000 May;58(4):286-92
10838493
J Urol. 1969 Aug;102(2):230-2
4895868
J Clin Oncol. 2002 Jan 1;20(1):197-204
11773170
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):652-6
11849786
Semin Oncol. 1999 Jun;26(3):259-69
10375083
Blood. 2005 Jan 15;105(2):496-502
15358629
J Urol. 1977 Nov;118(5):783-6
916101
Br J Urol. 1974 Oct;46(5):569-75
4420636
Clin Lymphoma. 2001 Jun;2(1):40-6
11707869
Ann Oncol. 1997 Aug;8(8):727-37
9332679
Nouv Rev Fr Hematol. 1995;37(5):267-72
8700650
Am J Med. 1986 Sep;81(3):515-24
3529957
Ann Oncol. 1990 Sep;1(5):383
2261381
J Clin Oncol. 2005 Aug 1;23(22):5027-33
15955905
J Pak Med Assoc. 1994 Apr;44(4):86-8
8072129
Clin Lymphoma. 2002 Dec;3(3):167-72
12521394
Clin Lymphoma. 2001 Sep;2(2):109-15
11707851
J Urol. 1996 Mar;155(3):943-6
8583613
Acta Oncol. 2004;43(8):758-65
15764222
J Clin Oncol. 2001 Jan 15;19(2):414-9
11208833
Cancer. 1995 Mar 1;75(5):1182-6
7850719
J Clin Oncol. 2003 Jan 1;21(1):20-7
12506165
Eur Urol. 2000 Dec;38(6):774-7
11111200
Ann Oncol. 2004 Jan;15(1):129-33
14679132
Oncology (Williston Park). 1998 Feb;12(2):185-91; discussion 192-5
9507520
J Clin Oncol. 1999 Sep;17(9):2854-8
10561362
Neurol Med Chir (Tokyo). 1986 Jan;26(1):68-70
2425280
Int J Oncol. 2005 Apr;26(4):1093-9
15754007
Cancer. 1980 Apr 1;45(7):1578-84
6989476
J Clin Oncol. 1995 Jun;13(6):1361-7
7751880
Australas Radiol. 1991 Aug;35(3):257-60
1763988
Am J Surg Pathol. 1994 Apr;18(4):376-90
8141430
Radiother Oncol. 1993 May;27(2):99-106
8356234
Neth J Med. 1991 Aug;39(1-2):92-100
1961354
Cancer Res. 1971 Nov;31(11):1860-1
5121694
J Urol. 1994 May;151(5):1162-70
8158751
Eur J Cancer. 1994;30A(12):1760-4
7880601
Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76
543449
Cancer. 2000 Jan 1;88(1):154-61
10618618
J Urol. 1977 Dec;118(6):1004-7
336911